Rare diseases
Investigational molecules
Locations
Recruiting trials first
15 clinical trials in this condition
Denmark
Norway
Belgium
PolandIn short
Type IIa hyperlipidaemia is a genetic condition that causes dangerously high levels of cholesterol in the blood from birth, significantly increasing the risk of heart disease and stroke even in young people. Understanding how to manage this condition through both established treatments and new research approaches can help protect your heart and improve your long-term health.
When someone is diagnosed with Type IIa hyperlipidaemia, also known as familial hypercholesterolemia, the main goal of treatment is to lower the dangerous levels of LDL cholesterol (low-density lipoprotein cholesterol, often called "bad cholesterol") that build up in the blood. This condition is inherited, meaning it runs in families, and causes cholesterol levels to be extremely high from birth or early childhood. Without proper treatment, this excess cholesterol creates fatty deposits called plaque inside the walls of arteries, which makes it harder for blood to flow through. Over time, these blockages can lead to heart attacks or strokes, sometimes even in children or young adults.
Treatment focuses on reducing LDL cholesterol to safe levels to prevent or slow down the buildup of plaque in arteries. The specific treatment approach depends on several factors, including how high the cholesterol levels are, whether the person inherited the faulty gene from one parent (heterozygous) or both parents (homozygous), the person's age, and whether they already have signs of heart disease. People who inherit the condition from both parents typically have much more severe symptoms and need more aggressive treatment starting in childhood.
Medical societies and guidelines recommend a combination of approaches to manage Type IIa hyperlipidaemia. These include standard treatments that have been proven effective over many years, such as cholesterol-lowering medications, as well as lifestyle changes like healthy eating and regular exercise. At the same time, researchers are studying new therapies in clinical trials to find even better ways to control cholesterol and protect the heart. Early detection and consistent, lifelong management are essential because the longer cholesterol remains high, the more damage accumulates in the arteries.
The foundation of treating Type IIa hyperlipidaemia involves medications called statins, which are drugs that block an enzyme in the liver responsible for making cholesterol. Statins are the first-line treatment recommended by medical guidelines because they have been proven to significantly lower LDL cholesterol levels and reduce the risk of heart attacks and strokes. Common statins include atorvastatin, rosuvastatin, simvastatin, and pravastatin. These medications work by inhibiting an enzyme called HMG-CoA reductase, which plays a key role in cholesterol production. When this enzyme is blocked, the liver makes less cholesterol and removes more LDL cholesterol from the bloodstream.
People with Type IIa hyperlipidaemia typically need high-potency statins at high doses to achieve adequate cholesterol reduction. High-potency statins like atorvastatin and rosuvastatin at high doses are more effective at reducing cardiovascular events than lower-potency statins or high-potency statins at low doses. The treatment is usually lifelong, as stopping the medication causes cholesterol levels to rise again. Doctors monitor cholesterol levels through blood tests, typically checking them within six weeks to six months after starting treatment to see if the medication is working effectively.
Many patients with Type IIa hyperlipidaemia need additional medications beyond statins because their cholesterol levels are so high that statins alone cannot bring them down to safe levels. One commonly used add-on medication is ezetimibe, which works differently from statins. Ezetimibe blocks the absorption of cholesterol from food in the intestines, preventing dietary cholesterol from entering the bloodstream. This complementary mechanism makes it a useful partner to statins.
Another class of medications used in standard treatment is bile acid sequestrants, such as cholestyramine. These drugs work in the digestive system by binding to bile acids, which are made from cholesterol. When bile acids are removed from the body, the liver must use more cholesterol to make new ones, which lowers cholesterol levels in the blood. However, these medications can cause digestive side effects like constipation and bloating, which sometimes makes them difficult for patients to tolerate long-term.
Niacin, also known as nicotinic acid, is a B vitamin that can lower LDL cholesterol and raise HDL cholesterol (the "good" cholesterol). While niacin can be helpful, it often causes side effects such as facial flushing (redness and warmth), itching, and upset stomach. These side effects can be uncomfortable enough that some people stop taking it.
For people with very severe Type IIa hyperlipidaemia, particularly those who inherited the condition from both parents (homozygous familial hypercholesterolemia), standard medications may not be enough. These patients may need specialized treatments such as LDL apheresis, a procedure similar to dialysis where blood is filtered through a machine that removes LDL cholesterol before returning the blood to the body. This treatment must be repeated regularly, typically every one to two weeks.
All cholesterol-lowering medications can cause side effects. Statins, the most commonly used drugs, can cause muscle pain or weakness in some people. Rarely, they can cause more serious muscle problems or affect liver function, which is why doctors monitor blood tests for liver enzymes. Other side effects reported with statins include digestive problems, fatigue, and in rare cases, new-onset diabetes. Despite these potential side effects, the cardiovascular benefits of statins generally outweigh the risks for people with Type IIa hyperlipidaemia, whose risk of heart disease is very high without treatment.
Lifestyle modifications are an essential part of standard treatment, even though medications are usually necessary. Patients are advised to follow a heart-healthy diet low in saturated fats, trans fats, and cholesterol. This means limiting red meat, full-fat dairy products, fried foods, and processed foods. Instead, the diet should emphasize vegetables, fruits, whole grains, fish, and foods containing healthy fats like olive oil. Regular physical activity of at least 150 minutes per week of moderate exercise helps improve cholesterol levels and overall heart health. Maintaining a healthy weight, quitting smoking, and limiting alcohol consumption are also important parts of comprehensive management.
Research into new treatments for Type IIa hyperlipidaemia has led to several innovative therapies being tested in clinical trials. One of the most promising developments involves medications called PCSK9 inhibitors. These are a newer class of drugs that work by blocking a protein called PCSK9 (proprotein convertase subtilisin/kexin type 9). This protein normally breaks down LDL receptors in the liver, which are responsible for removing LDL cholesterol from the blood. When PCSK9 is blocked, more LDL receptors remain active, allowing the liver to clear more cholesterol from the bloodstream.
PCSK9 inhibitors are given as injections under the skin, typically once or twice a month. Examples include evolocumab (marketed as Repatha) and alirocumab (marketed as Praluent). Clinical trials have shown that these medications can lower LDL cholesterol by an additional 50-60% when added to statin therapy. They have also been shown to reduce the risk of cardiovascular events like heart attacks and strokes. The safety profile has been generally positive, with the most common side effects being injection site reactions and, less commonly, flu-like symptoms. These medications are particularly useful for patients who cannot tolerate statins or who need additional cholesterol lowering beyond what statins can provide.
Clinical trials have progressed through multiple phases for PCSK9 inhibitors. Phase I trials tested the safety of these drugs in small numbers of healthy volunteers and confirmed they could be given safely. Phase II trials involved larger groups of patients with high cholesterol and demonstrated that the drugs effectively lowered LDL cholesterol levels. Phase III trials, which are large studies comparing the new treatment to existing treatments or placebo, showed that PCSK9 inhibitors not only lowered cholesterol but also reduced the risk of heart attacks and strokes over several years of follow-up.
Another innovative treatment approach being studied is called antisense oligonucleotide therapy. An example is mipomersen, which targets a specific genetic instruction (messenger RNA) that tells cells to make apolipoprotein B-100, a key component of LDL cholesterol particles. By blocking this genetic message, mipomersen reduces the production of LDL cholesterol. This medication is given as a weekly injection under the skin. Clinical trials have shown it can significantly lower LDL cholesterol in patients with severe familial hypercholesterolemia. However, side effects such as injection site reactions and potential effects on the liver have been observed, requiring careful monitoring.
Researchers are also investigating another medication called lomitapide, which works by inhibiting a protein called microsomal triglyceride transfer protein. This protein is essential for assembling and secreting lipoproteins that carry cholesterol. By blocking this protein, lomitapide reduces the amount of cholesterol released into the bloodstream. Lomitapide is taken as a daily pill and has shown effectiveness in lowering LDL cholesterol in patients with homozygous familial hypercholesterolemia, the most severe form of the condition. Clinical trials have demonstrated substantial reductions in LDL cholesterol levels. However, the medication can cause digestive side effects such as diarrhea, nausea, and abdominal discomfort, and it may affect liver function, requiring regular monitoring.
Clinical trials for Type IIa hyperlipidaemia are being conducted in multiple locations worldwide, including in the United States, Europe, and other regions. To participate in these trials, patients typically need to meet certain criteria, such as having confirmed familial hypercholesterolemia, having cholesterol levels above a certain threshold despite current treatments, and being willing to undergo regular monitoring and follow-up visits. Some trials focus specifically on patients who have not responded adequately to standard treatments or who cannot tolerate statins. Participation in clinical trials gives patients access to cutting-edge therapies before they become widely available and contributes to advancing medical knowledge that can help others with the same condition.
The mechanism of action for many of these experimental treatments involves targeting specific steps in the pathway of cholesterol production, transport, or breakdown. For instance, some therapies focus on increasing the number or activity of LDL receptors on liver cells, while others work by reducing the production of proteins needed to assemble cholesterol particles. By affecting these molecular targets, researchers hope to achieve greater cholesterol reduction with fewer side effects than older medications. Preliminary results from many of these trials have been encouraging, showing improvements in cholesterol levels and promising safety profiles, though long-term studies are still ongoing to confirm lasting benefits and identify any rare complications.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
